AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00974792
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01457703
Drug: Cetrorelix
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abolishes pituitary sensitivity to GnRH.
Trial: NCT01457703
Drug: Gonadorelin-GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH is used to stimulate the pituitary gland to produce LH and FSH.
Trial: NCT01457703
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An aromatase inhibitor.
Trial: NCT00121498
Drug: Lidocaine (local anesthetics) 20 ml of 1 % subcutaneously
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00632229
Drug: Paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
Trial: NCT02323217
Drug: Idazoxan
RxNorm normalized name: Idazoxan
DrugBank: Idazoxan (DB12551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan block of \[11C\]BU99008
Trial: NCT02323217
Drug: Isocarboxazid
RxNorm normalized name: Isocarboxazid
DrugBank: Isocarboxazid (DB01247)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isocarboxazid block of \[11C\]BU99008
Trial: NCT03133793
Drug: CoQ10
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
Trial: NCT03133793
Drug: D-Ribose Oral Powder
RxNorm normalized name: D-Ribose
DrugBank: Ribose (DB15073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
Trial: NCT04964180
Drug: Lidocaine 2% Injectable Solution
RxNorm normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 ml saline containing 200 mg 2%lidocaine intraperitoneal insilltation
Trial: NCT04544813
Drug: JNJ-77474462
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
Trial: NCT04544813
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
Trial: NCT02620774
Drug: Ceftolozane/tazobactam
RxNorm normalized name: CEFTOLOZANE/TAZOBACTAM
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
Trial: NCT02529072
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
Trial: NCT02059278
Drug: T-2345
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-2345 Ophthalmic Solution
Trial: NCT02059278
Drug: Xalatan
RxNorm normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Xalatan (latanoprost 0.005% ophthalmic solution)
Trial: NCT00766870
Drug: Lu AA34893
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
Trial: NCT00766870
Drug: Venlafaxine extended release
RxNorm normalized name: venlafaxine Extended Release Oral Tablet
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per oral, once daily, during 8 weeks, followed by a two-week tapering period
Trial: NCT02858622
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
Trial: NCT02858622
Drug: Pethidine
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
Trial: NCT01723982
Drug: Barusiban (FE 200440)
RxNorm normalized name: Fe
DrugBank: Barusiban (DB12292)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00736021
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
Trial: NCT01258803
Drug: Formoterol Fumarate DPI
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
Trial: NCT01258803
Drug: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Trial: NCT01258803
Drug: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Trial: NCT01258803
Drug: Mometasone Furoate DPI
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
Trial: NCT00777439
Drug: Domperidone
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
Trial: NCT03817658
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months.
Trial: NCT00140452
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
Trial: NCT04403334
Drug: Levofloxacin Ophthalmic
RxNorm normalized name: Levofloxacin Ophthalmic
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 ml of unpreserved 0.5% levofloxacin
Trial: NCT04403334
Drug: Moxifloxacin Ophthalmic
RxNorm normalized name: Moxifloxacin Ophthalmic
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 ml of unpreserved 0.5% moxifloxacin
Trial: NCT02180100
Drug: Terconazole Vaginal Suppository
RxNorm normalized name: terconazole Vaginal Insert
DrugBank: Terconazole (DB00251)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
Trial: NCT02180100
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
Trial: NCT02233686
Drug: XEN-D0501
RxNorm normalized name: XEN-D0501
DrugBank: XEN-D0501 (DB18673)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01539512
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib 150 mg tablet administered orally twice daily
Trial: NCT01539512
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
Trial: NCT01539512
Drug: Placebo to match idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo to match idelalisib administered orally twice daily
Trial: NCT03955146
Drug: Pamrevlumab
RxNorm normalized name: Pamrevlumab
DrugBank: Pamrevlumab (DB14952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamrevlumab will be administered per dose and schedule specified in the arm description.
Trial: NCT03475004
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Trial: NCT03475004
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.
Trial: NCT03475004
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.
Trial: NCT03059849
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of adalimumab will be increased by 40mg every 2 weeks.
Trial: NCT03473691
Drug: Glembatumumab Vedotin
RxNorm normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neo-adjuvant dose-dense doxorubicin 60 mg/m2 and Cytoxan 600 mg/m2 IV every 14 days for 4 cycles followed by GV 1.9 mg/kg IV every 21 days for 4 cycles.
Trial: NCT01074060
Drug: plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01516905
Drug: NM404
RxNorm normalized name: Nemolizumab
DrugBank: Nemolizumab (DB15252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of either 2.0mCi or 5.0mCi I-124 NM404
Trial: NCT04298229
Drug: Dapagliflozin 10 MG
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
Trial: NCT03487562
Drug: DWP14012 Amg
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 Amg
Trial: NCT03487562
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g
Trial: NCT03487562
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg
Trial: NCT00764465
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg BID
Trial: NCT00764465
Drug: Fosamprenavir
RxNorm normalized name: Fosamprenavir
DrugBank: Fosamprenavir (DB01319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1400 mg BID, 700 mg BID or 1400 mg QD
Trial: NCT00764465
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg BID, 100 mg QD
Trial: NCT03457701
Drug: Daprodustat
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
Trial: NCT03457701
Drug: rhEPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
Trial: NCT04017546
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral capsule
Trial: NCT03205423
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
Trial: NCT03718624
Drug: apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.
Trial: NCT03718624
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.
Trial: NCT03718624
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
Trial: NCT01867996
Drug: Retosiban
RxNorm normalized name: Retosiban
DrugBank: Retosiban (DB11818)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
Trial: NCT01867996
Drug: EFZ 600 mg
RxNorm normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
Trial: NCT04774029
Drug: Lidocaine induced basivertebral nerve block
RxNorm normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraosseous lidocaine basivertebral nerve block
Trial: NCT02746276
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
Trial: NCT02746276
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
Trial: NCT02924922
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01376076
Drug: Cariprazine
RxNorm normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
Trial: NCT01376076
Drug: Risperidone/Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
Trial: NCT01376076
Drug: Risperidone/Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
Trial: NCT00707551
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, administered as repeated doses.
Trial: NCT00707551
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended Release tablet, administered as repeated doses.
Trial: NCT00028015
Drug: SarCNU
RxNorm normalized name: SarCNU
DrugBank: 2-chloroethyl-3-sarcosinamide-1-nitrosourea (DB11688)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04600115
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
Trial: NCT04600115
Drug: O-15 labeled radioactive water
RxNorm normalized name: water, O-15
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
Trial: NCT00719511
Drug: Purified allergen dose 1 integrated in a Patch system
RxNorm normalized name: Purified oxgall
DrugBank: Ox bile extract (DB14016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicutaneous application of a patch
Trial: NCT00719511
Drug: Purified allergen dose 2 integrated in a Patch system
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicutaneous application of a patch
Trial: NCT00719511
Drug: Purified allergen dose 3 integrated in a Patch system
RxNorm normalized name: meningococcus A, purified polysaccharides antigen
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicutaneous application of a patch
Trial: NCT04129736
Drug: Teriflunomide 14 MG
RxNorm normalized name: teriflunomide 14 MG
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
Trial: NCT01733394
Drug: Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01733394
Drug: lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04054531
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04054531
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion
Trial: NCT04054531
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT01062230
Drug: Bortezomib (Velcade)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles.
Trial: NCT04192292
Drug: DPP4 Inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.